Loading
RAD51D (DNA repair protein RAD51 homolog 4) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 3 more.
Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Bind to single-stranded DNA (ssDNA) and has DNA-dependent ATPase activity. Part of the RAD51 paralog protein complex BCDX2 which acts in the BRCA1-BRCA2-dependent HR pathway.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Olaparib. Open Targets scores its association with cancer at 0.86 (direct and indirect evidence; datatypes genetic literature 0.88, affected pathway 0.87, literature 0.86, genetic association 0.87, somatic mutation 0.86).
In plain words · RAD51D (DNA repair protein RAD51 homolog 4) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 3 more.
RAD51D (DNA repair protein RAD51 homolog 4) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Breast cancer, Gastric & gastro-oesophageal junction cancer and 3 more.
Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Bind to single-stranded DNA (ssDNA) and has DNA-dependent ATPase activity.
No product in this corpus aims at RAD51D yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Germline variant: UniProt lists Breast-ovarian cancer, familial, 4 (BROVCA4) under involvement in disease, and the record is a DNA repair gene; the medicines linked to it act through the loss (synthetic lethality) or use the variant to pick patients. HPA RAD51D: RNA low tissue specificity; no normal tissue stained high. Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Breast cancer (all types), Gastric & gastro-oesophageal junction cancer, Prostate cancer, Colorectal cancer, Brain and spinal cord tumours (all types)); Open Targets associates it with 8 specific cancer types at or above 0.5 (hereditary breast ovarian cancer syndrome, ovarian cancer, ovarian carcinoma, RAD51D-related cancer predisposition, hereditary neoplastic syndrome, gastric cancer and more). (Rule 2 of scripts/fetch-target-specificity.ts.)
Sources: UniProt O75771; Human Protein Atlas RAD51D tissue; Open Targets ENSG00000185379 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Cartwright et al, Nucleic Acids Res, 1998, "Isolation of novel human and mouse genes of the recA/RAD51 recombination-repair gene family". Source.
Sources: HGNC HGNC:9823 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O75771 (protein name, function text, keywords and locations (REST API)); CIViC gene RAD51D (2 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, Castration-resistant Prostate Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000185379 (association with cancer (MONDO_0004992) 0.86; per-cancer scores at or above 0.5: colorectal cancer 0.59, gastric cancer 0.64, ovarian cancer 0.80, brain cancer 0.51, breast cancer 0.78 (GraphQL API, CC0))
Involved in the homologous recombination repair (HRR) pathway of double-stranded DNA breaks arising during DNA replication or induced by DNA-damaging agents. Bind to single-stranded DNA (ssDNA) and has DNA-dependent ATPase activity. Part of the RAD51 paralog protein complex BCDX2 which acts in the BRCA1-BRCA2-dependent HR pathway. Upon DNA damage, BCDX2 acts downstream of BRCA2 recruitment and upstream of RAD51 recruitment. BCDX2 binds predominantly to the intersection of the four duplex arms of the Holliday junction and to junction of replication forks. The BCDX2 complex was originally reported to bind single-stranded DNA, single-stranded gaps in duplex DNA and specifically to nicks in duplex DNA. Location: Nucleus; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Chromosome, telomere (UniProt). Locus 17q12 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA RAD51D tissue · HPA RAD51D pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
The germline finding is the practical lesson: a meaningful minority of biliary cancer patients carry inherited repair-gene mutations that matter for PARP inhibitor eligibility and for their relatives, which argues for germline testing alongside tumour sequencing.
It defines the gene list a TNBC germline panel should report on and shows the same genes apply in African American women, the population with the highest TNBC incidence.
The evidence that made germline testing standard for every man with metastatic prostate cancer, whatever his family history. It changes his treatment, because PARP inhibitors and platinum work better in these tumours, and it changes his relatives' screening, because BRCA2 carries breast, ovarian and pancreatic risk as well.
This cohort underpins the guideline shift to germline BRCA1/2 testing for all TNBC patients regardless of age or family history, and it is the prevalence figure the corpus uses for germline BRCA1 in TNBC.
Query for this target: (TITLE:"RAD51D" OR ABSTRACT:"RAD51D" OR TITLE:"RAD51 paralog D" OR ABSTRACT:"RAD51 paralog D" OR TITLE:"DNA repair protein RAD51 homolog 4" OR ABSTRACT:"DNA repair protein RAD51 homolog 4" OR TITLE:"R51H3" OR ABSTRACT:"R51H3" OR TITLE:"Trad" OR ABSTRACT:"Trad" OR TITLE:"HsTRAD" OR ABSTRACT:"HsTRAD") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RAD51D, not a curated reading list.
Shares Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing, Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer, Homologous recombination repair gene mutation in prostate cancer, CIViC.
Shares Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing, Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer, Homologous recombination repair gene mutation in prostate cancer, CIViC.
Shares Homologous recombination repair gene mutation in prostate cancer, CIViC, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Inherited DNA-repair gene mutations in men with metastatic prostate cancer, Homologous recombination repair gene mutation in prostate cancer, CIViC, Gastric & gastro-oesophageal junction cancer.
Shares Brain and spinal cord tumours (all types), Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Breast cancer (all types).
Shares Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing, Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, Homologous recombination repair gene mutation in prostate cancer.
Shares Brain and spinal cord tumours (all types), CIViC, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations, CIViC, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.